Seizure outcomes as an understudied metric in glioma clinical trials: A review of the ClinicalTrials.gov database
Despite their clinical significance, seizure outcomes are rarely and heterogeneously reported in clinical trials for adult-type diffuse gliomas. Incorporating standardized, seizure-specific endpoints may better align glioma research with patient-centered and disease-specific outcomes.
Authors
- Nathan A. Shlobin (ORCID: https://orcid.org/0000-0003-2079-6125)
- Sandra Leskinen (ORCID: https://orcid.org/0000-0001-8633-7859)
- Catherine A. Schevon (ORCID: https://orcid.org/0000-0002-4485-7933)
- Peter Canoll (ORCID: https://orcid.org/0000-0002-7001-0226)
- Arjun R. Adapa
- Guy M. McKhann (ORCID: https://orcid.org/0000-0002-9695-3564)
- Brian Gill (ORCID: https://orcid.org/0000-0001-5584-6714)
- Hannah Haile (ORCID: https://orcid.org/0009-0006-3974-4367)
Institutions
- Columbia University Irving Medical Center (US)
- Anna Needs Neuroblastoma Answers (US)
- Columbia University (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1093/noajnl/vdaf237
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00